不良研究所

Products
Nerve cells
Human iPSC-derived Alzheimer's disease model in glutamatergic neurons
不良研究所 Increased ratio of amyloid beta 42:40 in glutamatergic neurons APP V717I London mutation
不良研究所 Staining of glutamatergic neuron markers beta3 tubulin, MAP2 and VGLUT2 in the APP V717I het disease model
不良研究所 Brightfield imaging of iPSC derived neurons APP V717I het disease model shows glutamatergic neurons morphology
不良研究所 Glutamatergic Neurons APP V717I/WT neuronal marker gene expression by RT-qPCR
不良研究所 APP gene expression in Glutamatergic Neurons APP V717I het Alzheimer's disease model
不良研究所 Glutamatergic neurons APP V717I het are suitable for culture in 96-well and 384-well plates for screening applications
Human iPSC-derived Alzheimer's disease model in glutamatergic neurons
不良研究所 Increased ratio of amyloid beta 42:40 in glutamatergic neurons APP V717I London mutation
不良研究所 Staining of glutamatergic neuron markers beta3 tubulin, MAP2 and VGLUT2 in the APP V717I het disease model
不良研究所 Brightfield imaging of iPSC derived neurons APP V717I het disease model shows glutamatergic neurons morphology
不良研究所 Glutamatergic Neurons APP V717I/WT neuronal marker gene expression by RT-qPCR
不良研究所 APP gene expression in Glutamatergic Neurons APP V717I het Alzheimer's disease model
不良研究所 Glutamatergic neurons APP V717I het are suitable for culture in 96-well and 384-well plates for screening applications

cat no | io1067

ioGlutamatergic Neurons APP V717I/WT

Human iPSC-derived Alzheimer's disease model

  • Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days

  • Functional excitatory neurons engineered with the APP London mutation for Alzheimer's disease research

  • Disease-related phenotype demonstrated by increased ratio of A饾浗42:40 peptides vs. wild-type control

Place your order

Add to basket: 

Request a quote
Human iPSC-derived Alzheimer's disease model in glutamatergic neurons

Human iPSC-derived Alzheimer's disease model

不良研究所 Increased ratio of amyloid beta 42:40 in glutamatergic neurons APP V717I London mutation

Increased ratio of A饾浗42:40 seen in ioGlutamatergic Neurons APP V717I (London), as observed in Alzheimer鈥檚 disease

ioGlutamatergic Neurons APP V717I disease model cells show increased production of A饾浗38 and A饾浗42 peptides (involved in the amyloidogenic pathway), with no difference seen for A饾浗40 (A). This results in an increased ratio of A饾浗42:40 and no change in the A饾浗42:38 ratio (B).

  • ioGlutamatergic Neurons wild type (WT), APP V717I/WT (CL35, io1067S) and APP V717I/V717I (CL27, io1063S), were seeded at 30,000 cells/cm2 in 24-well plates and cultured for 30 days according to the user manual. Supernatant was collected at days 10, 20, and 30.
  • Levels of A饾浗38, A饾浗40 and A饾浗42 peptides were quantified using the V-PLEX A饾浗 Peptide Panel 1 (6E10) Kit ().
  • Concentrations of A饾浗38, A饾浗40, A饾浗42 were normalised to the calculated total number of cells per well.
  • Data were obtained from two independent experiments and are shown as mean 卤 SEM. Data were analysed statistically (at days 20 and 30) using Student鈥檚 t-tests comparing each clone to the wild type.
    * p<0.05 ** p<0.01 ***p<0.001
不良研究所 Staining of glutamatergic neuron markers beta3 tubulin, MAP2 and VGLUT2 in the APP V717I het disease model

ioGlutamatergic Neurons APP V717I/WT express neuron-specific markers comparably to the wild type control

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons APP V717I/WT (CL35) compared to the genetically matched control. 100X magnification.

不良研究所 Brightfield imaging of iPSC derived neurons APP V717I het disease model shows glutamatergic neurons morphology

ioGlutamatergic Neurons APP V717I/WT form structural neuronal networks by day 11

ioGlutamatergic Neurons APP V717I/WT mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.

不良研究所 Glutamatergic Neurons APP V717I/WT neuronal marker gene expression by RT-qPCR

ioGlutamatergic Neurons APP V717I/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming

Gene expression analysis demonstrates that ioGlutamatergic Neurons APP V717I/WT and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, while robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

不良研究所 APP gene expression in Glutamatergic Neurons APP V717I het Alzheimer's disease model

Disease-related APP is expressed in ioGlutamatergic Neurons APP V717I/WT following deterministic programming

RT-qPCR analysis demonstrates expression of the APP gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons APP V717I/WT at day 11 post-revival. Data normalised to HMBS, n=2 replicates.

不良研究所 Glutamatergic neurons APP V717I het are suitable for culture in 96-well and 384-well plates for screening applications

Industry leading seeding density

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Vial limit exceeded

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@不良研究所.

Human iPSC-derived Alzheimer's disease model

A rapidly maturing, physiologically relevant, functional system for investigating the role of the APP London mutation in early-onset Alzheimer's disease (AD). This in vitro disease cell model recapitulates an increased ratio of amyloid beta peptides A饾浗42:40, as observed in AD.

ioGlutamatergic Neurons APP V717I/WT are opti鈥憃x deterministically programmed excitatory neurons carrying a genetically engineered heterozygous V717I mutation in the APP gene encoding amyloid precursor protein. 

This disease model is part of an Alzheimer's disease panel of human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. A second clone for the APP V717I het mutation is available for scientists who wish to repeat their experiments in independent clones, please enquire. All disease models are genetically matched to the wild type control, ioGlutamatergic Neurons. Additional mutations in the AD panel include homozygous APP V717I , and heterozygous and homozygous APP KM670/671NL and PSEN1 M146L, alongside AD-relevant mutations in ioGABAergic Neurons and ioMicroglia.

Benchtop benefits

Increased ratio of A饾浗42:40 Alzheimer's disease phenotype

Disease related phenotype

Increased ratio of A饾浗42:40 peptides compared to the genetically matched control, measured by immunoassay.

Compare disease model with genetically matched control

Make True Comparisons

Pair the Alzheimer's disease model cells with the wild type glutamatergic neurons to investigate the impact of the APP missense mutation.

Glutamatergic neurons are quick to culture

Quick

The disease model cells and genetically matched control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Cells arrive ready to plate


ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons APP V717I/WT are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Product specifications

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male, age 55-60 years old (skin fibroblast),
Genotype APOE 3/4

Vial size

Small: >1 x 10鈦� viable cells, Evaluation pack*: 3 small vials of >1 x 10鈦� viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm虏

User storage

LN2 or -150掳C

Format

Cryopreserved cells

Genetic modification

Heterozygous V717I missense mutation in the APP gene

Applications

Alzheimer's disease research
Drug discovery and development
Disease modelling

Available clones

io1067 | APP V717I/WT (CL35)
io1068 | APP V717I/WT (CL58)

Product use

ioCells are for research use only

* Evaluation packs are intended for first-time users, or for existing users testing a new cell type or derivative. A user can request multiple evaluation packs as long as each one is for a different product, with only one pack allowed per product.
Technical data

Disease related phenotye

Increased ratio of A饾浗42:40 seen in ioGlutamatergic Neurons APP V717I (London), as observed in Alzheimer鈥檚 disease

不良研究所 Increased ratio of amyloid beta 42:40 in glutamatergic neurons APP V717I London mutation

ioGlutamatergic Neurons APP V717I disease model cells show increased production of A饾浗38 and A饾浗42 peptides (involved in the amyloidogenic pathway), with no difference seen for A饾浗40 (A). This results in an increased ratio of A饾浗42:40 and no change in the A饾浗42:38 ratio (B).

  • ioGlutamatergic Neurons wild type (WT), APP V717I/WT (CL35, io1067S) and APP V717I/V717I (CL27, io1063S), were seeded at 30,000 cells/cm2 in 24-well plates and cultured for 30 days according to the user manual. Supernatant was collected at days 10, 20, and 30.
  • Levels of A饾浗38, A饾浗40 and A饾浗42 peptides were quantified using the V-PLEX A饾浗 Peptide Panel 1 (6E10) Kit ().
  • Concentrations of A饾浗38, A饾浗40, A饾浗42 were normalised to the calculated total number of cells per well.
  • Data were obtained from two independent experiments and are shown as mean 卤 SEM. Data were analysed statistically (at days 20 and 30) using Student鈥檚 t-tests comparing each clone to the wild type.
    * p<0.05 ** p<0.01 ***p<0.001

Highly characterised and defined

ioGlutamatergic Neurons APP V717I/WT express neuron-specific markers comparably to the wild type control

不良研究所 Staining of glutamatergic neuron markers beta3 tubulin, MAP2 and VGLUT2 in the APP V717I het disease model

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons APP V717I/WT (CL35) compared to the genetically matched control. 100X magnification.

ioGlutamatergic Neurons APP V717I/WT form structural neuronal networks by day 11

不良研究所 Brightfield imaging of iPSC derived neurons APP V717I het disease model shows glutamatergic neurons morphology

ioGlutamatergic Neurons APP V717I/WT mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.

ioGlutamatergic Neurons APP V717I/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming

不良研究所 Glutamatergic Neurons APP V717I/WT neuronal marker gene expression by RT-qPCR

Gene expression analysis demonstrates that ioGlutamatergic Neurons APP V717I/WT and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, while robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Disease-related APP is expressed in ioGlutamatergic Neurons APP V717I/WT following deterministic programming

不良研究所 APP gene expression in Glutamatergic Neurons APP V717I het Alzheimer's disedase model

RT-qPCR analysis demonstrates expression of the APP gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons APP V717I/WT at day 11 post-revival. Data normalised to HMBS, n=2 replicates.

Industry leading seeding density

不良研究所 Glutamatergic neurons APP V717I het are suitable for culture in 96-well and 384-well plates for screening applications

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
Technical data

Increased ratio of A饾浗42:40

Increased ratio of A饾浗42:40 seen in ioGlutamatergic Neurons APP V717I (London), as observed in Alzheimer鈥檚 disease

不良研究所-Glutamatergic-Neurons-APP-V717I-Abeta42-40-ratio-quantification

ioGlutamatergic Neurons APP V717I disease model cells show increased production of A饾浗38 and A饾浗42 peptides (involved in the amyloidogenic pathway), with no difference seen for A饾浗40 (A). This results in an increased ratio of A饾浗42:40 and no change in the A饾浗42:38 ratio (B).

  • ioGlutamatergic Neurons wild type (WT), APP V717I/WT (CL35, io1067S) and APP V717I/V717I (CL27, io1063S), were seeded at 30,000 cells/cm2 in 24-well plates and cultured for 30 days according to the user manual. Supernatant was collected at days 10, 20, and 30.
  • Levels of A饾浗38, A饾浗40 and A饾浗42 peptides were quantified using the V-PLEX A饾浗 Peptide Panel 1 (6E10) Kit ().
  • Concentrations of A饾浗38, A饾浗40, A饾浗42 were normalised to the calculated total number of cells per well.
  • Data were obtained from two independent experiments and are shown as mean 卤 SEM. Data were analysed statistically (at days 20 and 30) using Student鈥檚 t-tests comparing each clone to the wild type.
    * p<0.05 ** p<0.01 ***p<0.001

How to culture ioGlutamatergic Neurons

In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.

Product resources

(LinkedValues: [{hs_name=ioGlutamatergic Neurons Wild Type and related disease models | User Manual, hs_id=161968263487, hs_path=glutamatergic-neurons, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=bit-bio ioGlutamatergic Neurons Day 14 Beta III Tubulin staining copy, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/ioGlutamatergic%20Neurons%20in%20Drug%20Discovery/bit-bio%20ioGlutamatergic%20Neurons%20Day%2014%20Beta%20III%20Tubulin%20staining%20copy.jpeg, height=1200}, year={label=2025, value=2025}, summary=<p>DOC-1289 4.0</p> <p>不良研究所</p> <p>2025<br><br></p>, date_published=1707955200000, sort_date=1713225600000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioGlutamatergic Neurons HTT 50CAG/WT, value=ioGlutamatergic Neurons HTT 50CAG/WT}, {label=ioGlutamatergic Neurons TDP-43 M337V Het, value=ioGlutamatergic Neurons TDP-43 M337V Het}, {label=ioGlutamatergic Neurons TDP-43 M337V Hom, value=ioGlutamatergic Neurons TDP-43 M337V Hom}, {label=ioGlutamatergic Neurons MAPT P301S/WT, value=ioGlutamatergic Neurons MAPT P301S/WT}, {label=ioGlutamatergic Neurons MAPT P301S/P301S, value=ioGlutamatergic Neurons MAPT P301S/P301S}, {label=ioGlutamatergic Neurons MAPT N279K/WT, value=ioGlutamatergic Neurons MAPT N279K/WT}, {label=Product information, value=Product information}, {label=User manual, value=user_manual}], media_contact=<p><span>DOC-1289 4.0</span></p> <p><span>不良研究所</span></p> <p><span>2025</span></p>, listing_button_label=Download}, {hs_name=CRISPRa-Ready ioGlutamatergic Neurons | User Manual, hs_id=186090210329, hs_path=crispr-activation-ready-glutamatergic-neurons, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=不良研究所-CRISPRa-ready-ioGlutamatergic-neurons-map2-staining, width=856, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioGlutamatergic%20Neurons/CRISPRa-Ready%20ioGlutamatergic%20Neurons/不良研究所-CRISPRa-ready-ioGlutamatergic-neurons-map2-staining.png, height=856}, year={label=2025, value=2025}, summary=V1<br>2025<br>不良研究所, date_published=1739404800000, sort_date=1739404800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=Product information, value=Product information}, {label=CRISPRa-Ready ioGlutamatergic Neurons, value=crispra-ready_ioglutamatergic_neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=User manual, value=user_manual}], media_contact=V1<br>2025<br>不良研究所, listing_button_label=Download}, {hs_name=CRISPRi-Ready ioGlutamatergic Neurons | User Manual, hs_id=186807423031, hs_path=crispri-ready-ioglutamatergic-neurons-user-manual, button_label=null, button_link=null, type={label=User manual, value=User manual}, thumbnail={alt_text=不良研究所-io1098-CRISPRi-ready-glutamatergic-neurons-tubb3-staining, width=856, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioGlutamatergic%20Neurons/CRISPRi-Ready%20ioGlutamatergic%20Neurons/不良研究所-io1098-CRISPRi-ready-glutamatergic-neurons-tubb3-staining.png, height=796}, year={label=2025, value=2025}, summary=V1<br>2025<br>不良研究所, date_published=1740960000000, sort_date=1740960000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=Product information, value=Product information}, {label=User manual, value=user_manual}], media_contact=V1<br>2025<br>不良研究所, listing_button_label=Download}, {hs_name=Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells, hs_id=161968263519, hs_path=modelling-neurodevelopment-webinar-2022, button_label=Explore ioGlutamatergic Neurons, button_link=/products/nerve-cells/glutamatergic-neurons-wild-type-io1001, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/BitBio2022/product-page/Colour%20webinar%20with%2060x%20Map2-com.jpg, height=732}, year={label=2022, value=2022}, summary=<p><span>Dr Deepak Srivastava | King鈥檚 College London<br><br></span><span></span></p>, date_published=1707436800000, sort_date=1649376000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=Webinars , value=webinars}, {label=Webinar | Modelling neurodevelopment , value=webinar_|_modelling_neurodevelopment}, {label=ioGABAergic Neurons!, value=iogabaergic_neurons}], media_contact=null, listing_button_label=Watch now}, {hs_name=Rethinking Developmental Biology With Cellular Reprogramming, hs_id=161968263524, hs_path=rethinking-developmental-biology-with-cellular-reprogramming, button_label=Explore ioCells, button_link=/discover-iocells, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1860, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Upcoming%20Webinars/Tech%20Nets%202023/不良研究所_ioGlutamatergic%20Neurons_20xMAP2(red)Hoescht(blue)_day12v2.png, height=1260}, year={label=2023, value=2023}, summary=<p>Mark Kotter | CEO and founder | 不良研究所</p> <p>Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |&nbsp; Stanford University</p>, date_published=1709164800000, sort_date=1681776000000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioMicroglia, value=ioMicroglia}, {label=Cell therapy, value=Cell therapy}, {label=ioSensory Neurons, value=ioSensory Neurons}, {label=ioOligodendrocyte-like cells, value=ioOligodendrocyte-like cells}, {label=Webinars , value=webinars}, {label=Webinar | Rethinking Developmental Biology, value=webinar_|_rethinking_developmental_biology}, {label=ioGABAergic Neurons!, value=iogabaergic_neurons}], media_contact=null, listing_button_label=Watch now}, {hs_name=Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming, hs_id=161968263525, hs_path=addressing-the-reproducibility-crisis-driving-genome-wide-consistency-in-cellular-reprogramming, button_label=Explore ioCells, button_link=/discover-iocells, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1860, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Upcoming%20Webinars/Tech%20Nets%2019th%20July%202023/不良研究所_ioGlutamatergic%20Neurons_60xMAP2(red)Hoescht(blue)TUBB3(blue)_day4.jpg, height=1260}, year={label=2023, value=2023}, summary=<p>Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | 不良研究所</p>, date_published=1709769600000, sort_date=1689724800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioSensory Neurons, value=ioSensory Neurons}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=Webinars , value=webinars}, {label=Webinar | Addressing the Reproducibility Crisis, value=webinar Addressing the Reproducibility Crisis}], media_contact=null, listing_button_label=Watch now}, {hs_name=Running Large-Scale CRISPR Screens in Human Neurons, hs_id=161968263528, hs_path=running-large-scale-crispr-screens-in-human-neurons, button_label=null, button_link=null, type={label=Webinar, value=Webinar}, thumbnail={alt_text=, width=1200, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Emails/Header%20images/Header%20Images%20-%20ICC%20only/Running%20Large-Scale%20CRISPR%20Screens%20in%20Human%20Neurons_email%20header.png, height=678}, year={label=2023, value=2023}, summary=<p>Emmanouil Metzakopian | Vice President, Research and Development | 不良研究所</p> <p>Javier Conde-Vancells | Director Product Management | 不良研究所</p>, date_published=1710460800000, sort_date=1700524800000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=CRISPR-Ready ioCells, value=CRISPR-Ready ioCells}, {label=CRISPR-Ready ioGlutamatergic Neurons, value=CRISPR-Ready ioGlutamatergic Neurons}, {label=CRISPR-Ready ioMicroglia, value=CRISPR-Ready ioMicroglia}, {label=Webinars , value=webinars}, {label=Webinar Running Large-Scale CRISPR Screens, value=webinar_running_large-scale_crispr_screens}], media_contact=null, listing_button_label=Watch now}, {hs_name=Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease, hs_id=183096620633, hs_path=human-ipsc-based-models-of-glial-cells-for-studying-neurodegenerative-disease, button_label=null, button_link=null, type={label=Webinar, value=Webinar}, thumbnail={alt_text=bitbio-oligodendrocyte-like-cells-O4-MBP-immunocytochemistry, width=1000, url=https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Website%20content/Product%20pages/ioOligodendrocyte-like%20cells/bitbio-oligodendrocyte-like-cells-O4-MBP-immunocytochemistry.jpg, height=1350}, year={label=2024, value=2024}, summary=Valentina Fossati, PhD | Senior Research Investigator | The New York Stem Cell Foundation<br><br>In锚s Ferreira | Senior Product Manager | 不良研究所, date_published=1732233600000, sort_date=1732233600000, tags=[{label=ioGlutamatergic Neurons, value=ioGlutamatergic Neurons}, {label=ioOligodendrocyte-like cells, value=ioOligodendrocyte-like cells}, {label=Webinars , value=webinars}, {label=Webinar | Human iPSC-Based Models of Glial , value=webinar_|_human_ipsc-based_models_of_glial}], media_contact=null, listing_button_label=Watch now}])
CRISPRi-Ready ioGlutamatergic Neurons | User Manual User manual
CRISPRi-Ready ioGlutamatergic Neurons | User Manual
V1
2025
不良研究所
Download
CRISPRa-Ready ioGlutamatergic Neurons | User Manual User manual
CRISPRa-Ready ioGlutamatergic Neurons | User Manual
V1
2025
不良研究所
Download
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease Webinar
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease
Valentina Fossati, PhD | Senior Research Investigator | The New York Stem Cell Foundation

In锚s Ferreira | Senior Product Manager | 不良研究所
Watch now
ioGlutamatergic Neurons Wild Type and related disease models | User Manual User manual
ioGlutamatergic Neurons Wild Type and related disease models | User Manual

DOC-1289 4.0

不良研究所

2025

Download
Running Large-Scale CRISPR Screens in Human Neurons Webinar
Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | 不良研究所

Javier Conde-Vancells | Director Product Management | 不良研究所

Watch now
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming Webinar
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | 不良研究所

Watch now
Rethinking Developmental Biology With Cellular Reprogramming Webinar
Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | 不良研究所

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells Webinar
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells

Dr Deepak Srivastava | King鈥檚 College London

Watch now

Cell culture hacks | human iPSC-derived glutamatergic neurons

Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.

Read the blog
不良研究所_3x2_ioGlutamatergic Neurons_MAP2_Hoescht_x20_hi.res (1)

Wild Type and Isogenic Disease Model cells: A true comparison

Further your disease research by pairing our wild type cells with isogenic disease models.

Discover ioWild Type cells
bitbio-vials-Wild_and_Disease-staggered-2500px_wide

ioCells catalogue

Human iPSC-derived cells

powered by opti-ox

Consistent. Defined. Scalable.

View all products
bitbio-cell_catalogue_header-with-tracker-Desktop-2500x1664